Climb Bio To Present New Clinical Data For Budoprutug In Immune Thrombocytopenia At 68th ASH Annual Meeting And Exposition

Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that it will present new clinical data for budoprutug in immune thrombocytopenia (ITP) at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition, which will be held in New Orleans, Louisiana from December 12-15, 2026.

Climb Bio will present data, including safety, B-cell depletion, and platelet data from all three dose cohorts from the ongoing Phase 1b trial of budoprutug, a novel anti-CD19 monoclonal antibody, in previously treated patients with primary immune thrombocytopenia.